Abstract

Application of metabolic magnetic resonance imaging measures such as cerebral blood flow in translational medicine is limited by the unknown link of observed alterations to specific neurophysiological processes. In particular, the sensitivity of cerebral blood flow to activity changes in specific neurotransmitter systems remains unclear. We address this question by probing cerebral blood flow in healthy volunteers using seven established drugs with known dopaminergic, serotonergic, glutamatergic and GABAergic mechanisms of action. We use a novel framework aimed at disentangling the observed effects to contribution from underlying neurotransmitter systems. We find for all evaluated compounds a reliable spatial link of respective cerebral blood flow changes with underlying neurotransmitter receptor densities corresponding to their primary mechanisms of action. The strength of these associations with receptor density is mediated by respective drug affinities. These findings suggest that cerebral blood flow is a sensitive brain-wide in-vivo assay of metabolic demands across a variety of neurotransmitter systems in humans.

Details

Title
Cerebral blood flow predicts differential neurotransmitter activity
Author
Dukart, Juergen 1   VIAFID ORCID Logo  ; Holiga, Štefan 1 ; Chatham, Christopher 1 ; Hawkins, Peter 2 ; Forsyth, Anna 3 ; McMillan, Rebecca 3 ; Myers, Jim 4 ; Lingford-Hughes, Anne R 4 ; Nutt, David J 5 ; Merlo-Pich, Emilio 1 ; Risterucci, Celine 1 ; Boak, Lauren 1 ; Umbricht, Daniel 1 ; Schobel, Scott 1 ; Liu, Thomas 6 ; Mehta, Mitul A 2 ; Zelaya, Fernando O 2 ; Williams, Steve C 2 ; Brown, Gregory 7 ; Paulus, Martin 7 ; Honey, Garry D 1 ; Muthukumaraswamy, Suresh 3 ; Hipp, Joerg 1 ; Bertolino, Alessandro 8 ; Sambataro, Fabio 9 

 F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland 
 Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom 
 School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand 
 Neuropsychopharmacology Unit, Imperial College London, London, United Kingdom 
 Veterans Affairs San Diego Healthcare System, San Diego, USA 
 Center for Functional MRI, University of California San Diego, 9500 Gilman Drive MC 0677, La Jolla, CA 92093, United States; Departments of Radiology, Psychiatry and Bioengineering, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States 
 University of California, San Diego, La Jolla, USA; Veterans Affairs San Diego Healthcare System, San Diego, USA 
 F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland; Institute Of Psychiatry, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari ‘Aldo Moro’, Bari, Italy 
 F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland; Department of Experimental and Clinical Medical Sciences (DISM), University of Udine, Udine, Italy 
Pages
1-11
Publication year
2018
Publication date
Mar 2018
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2011280323
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.